{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:51:37Z","timestamp":1777441897068,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Vifor"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cld.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T09:30:12Z","timestamp":1492767012000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rheumatologic Manifestations of Hepatitis C Virus Infection"],"prefix":"10.1016","volume":"21","author":[{"given":"Patrice","family":"Cacoub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clo\u00e9","family":"Comarmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Claire","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.cld.2017.03.002_bib1","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2017.03.002_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","article-title":"Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin\u2019s lymphoma, and cancer","volume":"7","author":"Ferri","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2017.03.002_bib3","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3760\/cma.j.issn.0366-6999.20132988","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China","volume":"127","author":"Cheng","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cld.2017.03.002_bib5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s10067-010-1463-x","article-title":"Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians","volume":"29","author":"Mohammed","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cld.2017.03.002_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12891-015-0552-z","article-title":"Prevalence and risk factors for patient-reported joint pain among patients with HIV\/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection","volume":"16","author":"Ogdie","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.cld.2017.03.002_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3899\/jrheum.090790","article-title":"Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy","volume":"37","author":"Landau","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cld.2017.03.002_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/art.30319","article-title":"Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis","volume":"63","author":"Terrier","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005792-200001000-00005","article-title":"Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d\u2019Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l\u2019Hepatite C","volume":"79","author":"Cacoub","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cld.2017.03.002_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.57.12.728","article-title":"Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection","volume":"57","author":"Lee","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.cld.2017.03.002_bib12","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.cld.2017.03.002_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extra-hepatic manifestations of hepatitis C\u2014a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2017.03.002_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13075-015-0766-3","article-title":"How hepatitis C virus modifies the immunological profile of Sj\u00f6gren syndrome: analysis of 783 patients","volume":"17","author":"Brito-Zer\u00f3n","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cld.2017.03.002_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.md.0000157397.30055.c9","article-title":"Sj\u00f6gren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases","volume":"84","author":"Ramos-Casals","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cld.2017.03.002_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0002-9440(10)63964-8","article-title":"In situ detection of hepatitis C virus RNA in salivary glands","volume":"158","author":"Arrieta","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cld.2017.03.002_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1073\/pnas.94.1.233","article-title":"Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes","volume":"94","author":"Koike","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2017.03.002_bib18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/liv.12227","article-title":"Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response","volume":"33","author":"Khairy","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2017.03.002_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/jcp.2006.046276","article-title":"Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C","volume":"61","author":"Hsieh","year":"2008","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.cld.2017.03.002_bib20","doi-asserted-by":"crossref","first-page":"871401","DOI":"10.1155\/2012\/871401","article-title":"Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection","volume":"2012","author":"Himoto","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"187","key":"10.1016\/j.cld.2017.03.002_bib21","first-page":"6550","article-title":"Expansion of functionally anergic CD21-\/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity","volume":"2011","author":"Terrier","year":"1950","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cld.2017.03.002_bib22","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.03.002_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/gene.2014.41","article-title":"Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis","volume":"15","author":"Zignego","year":"2014","journal-title":"Genes Immun"},{"key":"10.1016\/j.cld.2017.03.002_bib24","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.30274","article-title":"Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc\u03b3 receptors","volume":"63","author":"Gragnani","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jmv.1095","article-title":"Study of the infection of human blood derived monocyte\/macrophages with hepatitis C virus in\u00a0vitro","volume":"65","author":"Caussin-Schwemling","year":"2001","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cld.2017.03.002_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","article-title":"Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme","volume":"102","author":"Muramatsu","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.cld.2017.03.002_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/acr.22463","article-title":"Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection","volume":"67","author":"Patel","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.cld.2017.03.002_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/liv.13064","article-title":"Chronic hepatitis C virus infection, a new cardiovascular risk factor?","volume":"36","author":"Domont","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2017.03.002_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","article-title":"Myocardial injury in patients with chronic hepatitis C infection","volume":"58","author":"Maruyama","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.002_bib30","doi-asserted-by":"crossref","first-page":"e2113","DOI":"10.1097\/MD.0000000000002113","article-title":"Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cld.2017.03.002_bib31","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.002_bib32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/apt.12391","article-title":"Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan","volume":"38","author":"Hsu","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2017.03.002_bib33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27228","article-title":"Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C","volume":"60","author":"Elkrief","year":"2014","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.cld.2017.03.002_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep.27212","article-title":"Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study","volume":"60","author":"Huang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.002_bib35","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.25585","article-title":"Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy","volume":"128","author":"Hung","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cld.2017.03.002_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2036.2011.04716.x","article-title":"Meta-analysis: insulin resistance and sustained virological response in hepatitis C","volume":"34","author":"Eslam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2017.03.002_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2004.10.031","article-title":"Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study","volume":"42","author":"Mazzaro","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.002_bib38","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis: a long-term followup study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","article-title":"Cryoglobulinemia vasculitis","volume":"128","author":"Cacoub","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2017.03.002_bib40","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3899\/jrheum.100092","article-title":"Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-\u03b12a treatment for chronic hepatitis C infection","volume":"37","author":"Yang","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cld.2017.03.002_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/1756-0500-6-437","article-title":"Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature","volume":"6","author":"Cacopardo","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.cld.2017.03.002_bib42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0961203309353172","article-title":"Systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C","volume":"19","author":"Onishi","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.cld.2017.03.002_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2008.12.008","article-title":"Interferon alpha and neuromuscular disorders","volume":"207","author":"St\u00fcbgen","year":"2009","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.cld.2017.03.002_bib44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","article-title":"Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study","volume":"46","author":"Gragnani","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2017.03.002_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFN\u03b1\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis","volume":"62","author":"Saadoun","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.002_bib46","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.03.002_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.03.002_bib48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","article-title":"Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection","volume":"150","author":"Sulkowski","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2017.03.002_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/HMER.S62014","article-title":"Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life","volume":"8","author":"Pol","year":"2016","journal-title":"Hepat Med"},{"key":"10.1016\/j.cld.2017.03.002_bib50","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus\u2013associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2017.03.002_bib51","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.002_bib52","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A\u00a0randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib53","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A\u00a0randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus Peg-interferon-alpha\/ribavirin compared with Peg-interferon-alpha\/ribavirin in hepatitis C-related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.002_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.002_bib56","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1002\/art.25000","article-title":"Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis","volume":"60","author":"S\u00e8ne","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.002_bib57","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V84.10.3336.3336","article-title":"Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study","volume":"84","author":"Dammacco","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.002_bib58","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1159\/000065023","article-title":"Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis","volume":"91","author":"Hausfater","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.cld.2017.03.002_bib59","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.cld.2017.03.002_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2011.09.015","article-title":"Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition","volume":"56","author":"Byrnes","year":"2012","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T18:16:00Z","timestamp":1719166560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326117300193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1089326117300193"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2017.03.002","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatologic Manifestations of Hepatitis C Virus Infection","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}